Monday, January 08, 2018 10:15 PM ET
Insider Selling in FibroGen (FGEN) Shares Continues
A SEC filing today indicated a substantial insider sale of FibroGen shares as — Thomas B Neff, Director and Officer — sold 38,636 shares in the company having a market value of approximately $1,839,553. There have been 5 insiders with buy/sell transactions in the past 90 days prior to this filing. These trades have resulted in the acquisition of 3,500 company shares and the sale of 173,746 company shares over this time period. Adding the most recent activity to this 90-day history indicates insider trades have been net sales of 208,882 shares and have averaged 35,980 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at FibroGen is greater than its 191-company peer group average. The Biotechnology & Medical Research peer group saw 162 buy/sell trades during this period for an average of 0.8 transactions per company. However, the number of shares traded per transaction by FibroGen insiders is lower than its peers. Within the peer group there were 26,685,061 shares purchased and 11,490,516 shares sold with company insiders having bought 126,621 shares on average over this time period.
In determining significant insider buying and selling, trades reported to the SEC that involve awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers have been eliminated in data sourced to evaluate and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.